Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to expose patients with OA to calcitonin and to determine plasma
calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin and 200 IU nasal
calcitonin. Also the purpose is to assess the effect of different doses of oral calcitonin
(0.6 mg and 0.8 mg oral) and 200 IU nasal calcitonin compared to placebo on serum CTX-I and
CTX-II. Finally to assess the tolerance profile of different doses/formulations of oral
calcitonin compared to placebo.